Condition Directory

Multiple Myeloma clinical trials

Directory of U.S. ClinicalTrials.gov public records for Multiple Myeloma. Browse Multiple Myeloma recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced October 23, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2317

Shown on this page

Current sort

How Multiple Myeloma studies are organized in the registry

Myeloma listings distinguish newly diagnosed from relapsed/refractory disease in their titles, and precursor conditions — smoldering myeloma and MGUS — are usually registered as separate condition terms. Cell-based and antibody platforms (CAR-T, bispecific antibodies) appear by name in many current titles.

Terms that often appear in related listings

relapsed refractory myeloma smoldering myeloma CAR-T bispecific

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 37–48 of 2,317 matching trials for Multiple Myeloma.

Live ClinicalTrials.gov results.

Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search

Conditions: Plasma Cell Myeloma
Interventions: Bortezomib, Daratumumab, Dexamethasone, Iberdomide; Drug · Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer, Pesticide Exposures, Lymphoma, Multiple Myeloma
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 89,655 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1993
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Interventions: LLS Program; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Miami, Florida • Chicago, Illinois • San Antonio, Texas

Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin, Leukemia-Lymphoma, Adult T-Cell, Hodgkin Disease, Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Neoplasms, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Biopsy; Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Months and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 16
States / cities: Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 13 more

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Carfilzomib, Computed Tomography, Dexamethasone, FDG-Positron Emission Tomography, Fludeoxyglucose F-18, Pomalidomide, Teclistamab; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Duarte, California

Conditions: Plasma Cell Myeloma
Interventions: Belantamab Mafodotin, Lenalidomide; Biological · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Multiple Myeloma
Interventions: Selinexor; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: AZD4045, Daratumumab, Aldesleukin; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 10
States / cities: Duarte, California • Denver, Colorado • Tampa, Florida + 7 more

Conditions: Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
Interventions: Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Andrew Yee, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions: NT-I7, Placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

About this Multiple Myeloma clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Multiple Myeloma as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Multiple Myeloma.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Multiple Myeloma clinical trials

How Multiple Myeloma studies are organized in the registry

Filter and sort this condition

Live official records

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Agriculture Health Study

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

Collection of Tissue Samples for Cancer Research

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant

Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

About this Multiple Myeloma clinical trials directory page